Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Conditions

• Leukemia, Myelomonocytic, Acute

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Erlotinib — DRUG
  Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.

Study Details

This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.

Key Dates

First listed

Aug 3, 2010

Start date

Jul 31, 2010

Status verified

Oct 2023

Primary completion

Mar 31, 2012

Completion

Mar 31, 2012

Study Design

Enrollment

11 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Erlotinib

Primary Outcome Measure

Overall Response Rate (Defined as Partial Remission or Better) to 3 Months of Treatment With Erlotinib [ Time Frame: 3 months of treatment with erlotinib ]

Locations (1)

Find similar trials in Indianapolis, IN